



: Mrs.GOSAVI AMRUTA ASHOKGIRI

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538

Ref Doctor

: CKHAOPV97832

Emp/Auth/TPA ID

: Dr.SELF

Collected

: 27/May/2023 10:12AM

Received : 27/May/2023 12:45PM

Reported

: 27/May/2023 03:07PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD-EDTA

: 458697

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN







Test Name

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538 : CKHAOPV97832

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 458697

Collected : 27/May/2023 10:12AM

Received : 27/May/2023 12:45PM Reported : 27/May/2023 03:07PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	13.9	g/dL	12-15	Spectrophotometer
PCV	41.70	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.69	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	88.8	fL	83-101	Calculated
MCH	29.6	pg	27-32	Calculated
MCHC	33.4	g/dL	31.5-34.5	Calculated
R.D.W	12.9	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	7,150	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	68.1	%	40-80	Electrical Impedance
LYMPHOCYTES	26.7	%	20-40	Electrical Impedance
EOSINOPHILS	1.1	%	1-6	Electrical Impedance
MONOCYTES	3.9	%	2-10	Electrical Impedance
BASOPHILS	0.2	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4869.15	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	1909.05	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	78.65	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	278.85	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	14.3	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	286000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	2	mm at the end of 1 hour	0-20	Modified Westergre

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 12







Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538 : CKHAOPV97832

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 458697

Collected

: 27/May/2023 10:12AM

Received

: 27/May/2023 12:45PM : 27/May/2023 02:37PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2	324
--	-----

Test Name Result Unit Bio. Ref. Range Method

BLOOD GROUP ABO AND RH FACTOR , WHOLE BLOOD-EDTA					
BLOOD GROUP TYPE	В	Microplate Hemagglutination			
Rh TYPE	Positive	Microplate Hemagglutination			





: Mrs.GOSAVI AMRUTA ASHOKGIRI

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538

Ref Doctor

: CKHAOPV97832

: Dr.SELF Emp/Auth/TPA ID : 458697

Collected

: 27/May/2023 12:39PM

Received

: 27/May/2023 03:54PM

Reported

: 27/May/2023 05:24PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING, NAF PLASMA	94	mg/dL	70-100	HEXOKINASE
------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines

Fasting Glucose Values in mg/d L	Interpretation
<100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes

GLUCOSE, POST PRANDIAL (PP), 2	110	mg/dL	70-140	HEXOKINASE
HOURS, NAF PLASMA				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach

Page 4 of 12







: Mrs.GOSAVI AMRUTA ASHOKGIRI

: 36 Y 6 M 0 D/F

Age/Gender UHID/MR No

: CKHA.0000066538

Visit ID

: CKHAOPV97832

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 458697

Collected

Reported

: 27/May/2023 10:12AM

Received

: 27/May/2023 12:44PM : 27/May/2023 03:22PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD-EDTA	5.1	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD-EDTA	100	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA):

REFERENCE GROUP	HBA1C IN %
NON DIABETIC ADULTS >18 YEARS	<5.7
AT RISK (PREDIABETES)	5.7 - 6.4
DIAGNOSING DIABETES	≥ 6.5
DIABETICS	
· EXCELLENT CONTROL	6 – 7
· FAIR TO GOOD CONTROL	7 - 8
· UNSATISFACTORY CONTROL	8 – 10
· POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control

Page 5 of 12







Test Name

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538

Ref Doctor

: CKHAOPV97832

: Dr.SELF Emp/Auth/TPA ID : 458697

Collected

: 27/May/2023 10:12AM : 27/May/2023 01:02PM

Reported Status

Received

: 27/May/2023 02:08PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 Result Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	104	mg/dL	<200	CHO-POD
TRIGLYCERIDES	54	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	58	mg/dL	<130	Calculated
LDL CHOLESTEROL	47.68	mg/dL	<100	Calculated
VLDL CHOLESTEROL	10.72	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.28		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	<u>≥</u> 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.





Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No

: CKHA.0000066538

Ref Doctor

Visit ID

: CKHAOPV97832

: Dr.SELF Emp/Auth/TPA ID : 458697

Collected

: 27/May/2023 10:12AM

Received

: 27/May/2023 01:02PM : 27/May/2023 02:08PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.77	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.57	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	13.77	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	23.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	62.99	U/L	30-120	IFCC
PROTEIN, TOTAL	6.58	g/dL	6.6-8.3	Biuret
ALBUMIN	4.20	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.38	g/dL	2.0-3.5	Calculated
A/G RATIO	1.76	-	0.9-2.0	Calculated





Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No

Visit ID

: CKHA.0000066538

Ref Doctor

: CKHAOPV97832

: Dr.SELF Emp/Auth/TPA ID : 458697

Collected : 27/May/2023 10:12AM

Received : 27/May/2023 01:02PM Reported : 27/May/2023 02:08PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

	DEPARTMENT OF BIOCHEMISTRY					
ARCO	ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
	Test Name	Result	Unit	Bio. Ref. Range	Method	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM						
CREATININE	0.74	mg/dL	0.55-1.02	Modified Jaffe, Kinetic		
UREA	34.32	mg/dL	17-43	GLDH, Kinetic Assay		
BLOOD UREA NITROGEN	16.0	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	3.46	mg/dL	2.6-6.0	Uricase PAP		
CALCIUM	9.65	mg/dL	8.8-10.6	Arsenazo III		
PHOSPHORUS, INORGANIC	3.46	mg/dL	2.5-4.5	Phosphomolybdate Complex		
SODIUM	139.93	mmol/L	136–146	ISE (Indirect)		
POTASSIUM	4.5	mmol/L	3.5–5.1	ISE (Indirect)		
CHLORIDE	105.54	mmol/L	101–109	ISE (Indirect)		





: Mrs.GOSAVI AMRUTA ASHOKGIRI

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538

: CKHAOPV97832

Ref Doctor Emp/Auth/TPA ID : Dr.SELF

: 458697

Collected

: 27/May/2023 10:12AM

Received

: 27/May/2023 01:02PM

Reported

: 27/May/2023 02:08PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT	OF BIC	CHEMISTRY
------------	--------	-----------

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY232	:4
--	----

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	12.27	U/L	<38	IFCC
(GGT) . SERUM				





Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No Visit ID

: CKHA.0000066538 : CKHAOPV97832

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 458697

Collected : 27/May/2023 10:12AM

Received : 27/May/2023 01:02PM Reported : 27/May/2023 02:11PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT	OF	IMMUNOLOGY
------------	----	-------------------

ARCOFEMI - MEDIWHEEL - FULL BODY	HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	0.83	ng/mL	0.7-2.04	CLIA		
THYROXINE (T4, TOTAL)	8.53	μg/dL	6.09-12.23	CLIA		
THYROID STIMULATING HORMONE (TSH)	4.883	μIU/mL	0.34-5.60	CLIA		

Comment:

Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night and the nadir occurring between 10 a.m. and 4 p.m.In primary hypothyroidism, thyroid-stimulating hormone (TSH) levels will be elevated. In primary hyperthyroidism, TSH levels will be low. Elevated or low TSH in the context of normal free thyroxine is often referred to as subclinical hypo- or hyperthyroid-ism, respectively. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.

Note:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 – 3.0





Age/Gender

Visit ID

: 36 Y 6 M 0 D/F

UHID/MR No

: CKHA.0000066538

Ref Doctor

: CKHAOPV97832

: Dr.SELF Emp/Auth/TPA ID : 458697

Test Name

Collected : 27/May/2023 10:12AM

Received : 27/May/2023 03:32PM Reported : 27/May/2023 04:50PM

Status : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY					
DEFARTIMENT OF CLINICAL PATROLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

COMPLETE URINE EXAMINATION (C	JE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	>1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY			
PUS CELLS	2 - 3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1 - 2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY





: Mrs.GOSAVI AMRUTA ASHOKGIRI

Age/Gender

: 36 Y 6 M 0 D/F

UHID/MR No

: CKHA.0000066538

Visit ID Ref Doctor : CKHAOPV97832

Emp/Auth/TPA ID

: Dr.SELF : 458697

Collected

: 27/May/2023 10:12AM

Received

: 27/May/2023 03:33PM

Reported Status

: 27/May/2023 05:06PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTME	:NT OF C	IMICAL	OGV

Test Name	Result	Unit	Bio. Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE Dipstick
URINE GLUCOSE(FASTING)	NEGATIVE	NEGATIVE Dipstick

*** End Of Report ***

Dr Sneha Shah

Dr Sanjay Ingle MBBS, MD (Pathology) M.B.B.S, MD(Pathology) Consultant Pathologist Consultant Pathologist

Apollo Health and Lifestyle Limited (CIN - U85110TG2000PLC115819)



Patient Name : Mrs. GOSAVI AMRUTA ASHOKGIRI Age/Gender : 36 Y/F

UHID/MR No. : CKHA.0000066538 **OP Visit No** : CKHAOPV97832

Sample Collected on : Reported on : 27-05-2023 16:08

Ref Doctor : SELF **Emp/Auth/TPA ID** : 458697

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION:

No obvious abnormality seen

Dr. SANKET KASLIWAL MBBS DMRE

Radiology



Patient Name : Mrs. GOSAVI AMRUTA ASHOKGIRI Age/Gender : 36 Y/F

 UHID/MR No.
 : CKHA.0000066538
 OP Visit No
 : CKHAOPV97832

 Sample Collected on
 : 27-05-2023 13:12

Ref Doctor : SELF **Emp/Auth/TPA ID** : 458697

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

Liver: It appears normal in size, shape and shows normal echotexture. No focal lesion is noted. No e/o IHBR dilatation is seen. Portal vein and CBD appear normal in dimensions at porta hepatis.

Gall bladder: It is partially distended. No calculus or sludge noted.

Spleen: It appears normal in size, shape and echotexture. No focal lesion is noted.

Pancreas: It appears normal in size, shape and echotexture. No focal lesion / pancreatic ductal dilatation / calcification noted.

Right kidney: Normal in size ms 9.8 x 4.1 cms, shape, location with smooth outlines and normal echotexture. CM differentiation is well maintained. No calculus or hydronephrosis seen.

Left kidney: Normal in size ms 10.4 x 4.3 cms, shape, location with smooth outlines and normal echotexture. CM differentiation is well maintained. No calculus or hydronephrosis seen.

No retroperitoneal lymphadenopathy is seen. Aorta and I.V.C. appear normal.

Urinary bladder: It is partially distended and appears normal. No echoreflective calculus or soft tissue mass noted. Both U-V junction appear normal.

Uterus:is anteverted, and measures 8.5 x 3.5 x 5.4 cms. No focal lesion seen. Endometrial thickness is 8.7 mm.

Right ovary: measures 3.1 x 2.3 cms. **Left ovary: not visualised PA.**

Visualised bowel loops appear normal.

IMPRESSION :

NO SIGNIFICANT ABNORMALITY.

Clinical correlation suggested.....

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. SANKET KASLIWAL
MBBS DMRE

Radiology